☆ 4.7 Article

Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years

ALZHEIMERS & DEMENTIA (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years

Hannah Stocker et al.

Summary: This study aimed to investigate the association between blood biomarkers and Alzheimer's disease (AD) risk. It found that GFAP may be an early biomarker for AD, while p-tau181 and NfL are associated with intermediate risk. The impact of cardiovascular health on p-tau181 and NfL should be considered in risk stratification.

ALZHEIMERS & DEMENTIA (2023)

Add to Collection

Article Clinical Neurology

Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group

Inge M. W. Verberk et al.

Summary: Pre-analytical sample handling can impact Alzheimer's disease blood-based biomarkers. Different collection tube types resulted in varying values of assessed markers, with delayed centrifugation and storage affecting A beta and t-tau. Standardized operating procedures for plasma handling were constructed to facilitate the incorporation of blood-based biomarkers into research and clinical settings.

ALZHEIMERS & DEMENTIA (2022)

Add to Collection

Article Clinical Neurology

Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease

Pratishtha Chatterjee et al.

Summary: This study found that GFAP and p-tau have good diagnostic and longitudinal monitoring potential in preclinical Alzheimer's disease. Combining GFAP with other proteins can improve diagnostic accuracy.

ALZHEIMERS & DEMENTIA (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Prediction of clinical diagnosis of Alzheimer's disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years

H. Stocker et al.

Summary: The study found that the AD polygenic risk score (PRS) and APOE status could effectively predict the clinical diagnosis of AD, VD, MD, and all-cause dementia in a community-based cohort.

MOLECULAR PSYCHIATRY (2021)

Add to Collection

Article Clinical Neurology

Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum

Alexis Moscoso et al.

Summary: Measurement of tau phosphorylated at threonine 181 (p-tau181) in blood plasma is proposed as a specific biomarker for Alzheimer's disease. Longitudinal study reveals that plasma p-tau181 increases before amyloid-beta markers reach abnormal levels, correlating with amyloid-beta pathology. Plasma p-tau181 also shows associations with widespread cortical tau aggregation and may be a useful diagnostic and screening tool for Alzheimer's disease.

BRAIN (2021)

Add to Collection

Review Clinical Neurology

Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease

Antoine Leuzy et al.

Summary: Recent advances in CSF and blood-based biomarkers of Alzheimer's disease lesions include the introduction of fully automated assays, certified reference materials for CSF A beta 42, and a unified protocol for sample handling. These developments support the reliability and availability of biomarkers, such as A beta, P-tau, and NfL, in both CSF and blood, with potential applications in clinical practice and trials.

CURRENT OPINION IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

Alexis Moscoso et al.

Summary: This study found that plasma p-tau181 could serve as a marker for predicting and monitoring neurodegeneration and cognitive decline, with greater AD specificity compared to plasma NfL, holding important implications for monitoring AD progression in clinical practice and treatment trials.

JAMA NEUROLOGY (2021)

Add to Collection

Article Psychiatry

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease

Pratishtha Chatterjee et al.

Summary: The study found that plasma GFAP levels are elevated in cognitively normal older adults at risk of AD, indicating that astrocytic damage or activation may start from the pre-symptomatic stage of the disease and is associated with brain Aβ load. The potential of plasma GFAP to contribute to a diagnostic blood biomarker panel, along with plasma Aβ 1-42/Aβ 1-40 ratios, for cognitively normal older adults at risk of AD was highlighted by the observations from the present study.

TRANSLATIONAL PSYCHIATRY (2021)

Add to Collection

Article Clinical Neurology

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease

Oskar Hansson et al.

Summary: The study found that high plasma tau levels were associated with hypometabolism and cortical atrophy, and these associations were observed only in Aβ-positive participants. Plasma phosphorylated tau may help identify and track processes linked to neurodegeneration in Alzheimer's disease.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis

Leon Beyer et al.

Summary: The study shows that measuring the misfolding of TDP-43 in the cerebrospinal fluid of ALS patients using immuno-infrared sensor technology has the potential to serve as a biomarker for ALS. The technology can accurately distinguish ALS patients from other control groups.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

Niklas Mattsson-Carlgren et al.

Summary: Plasma levels of phospho-tau217 (P-tau217) accurately differentiate Alzheimer's disease dementia from other dementias, with increasing levels reflecting both beta-amyloid plaques and tau tangles. The correlation between P-tau217 concentrations and beta-amyloid PET is stronger in early disease stages, while in late stages, there is a stronger correlation with both beta-amyloid and tau PET results. P-tau217 mediates the association between beta-amyloid and tau, especially for tau outside of the medial temporal lobe.

EMBO MOLECULAR MEDICINE (2021)

Add to Collection

Editorial Material Clinical Neurology

Glial fibrillary acidic protein: a blood biomarker to differentiate neurodegenerative from psychiatric diseases

Henrik Zetterberg

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures

Sebastian Palmqvist et al.

Summary: Plasma P-tau, in combination with plasma phospho-tau and other biomarkers, along with clinical tests and APOE genotyping, can accurately predict the risk of Alzheimer's disease dementia, improving diagnostic prediction and facilitating recruitment for clinical trials.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

Nicholas C. Cullen et al.

Summary: Plasma biomarkers of amyloid, tau, and neurodegeneration (ATN) can predict clinical deterioration in cognitively unimpaired elderly individuals. A combination of these biomarkers in plasma can reduce the required sample size in clinical trials, making them more feasible and cost-effective while improving efficacy.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Clinical Neurology

Head-to-Head Comparison of 8 Plasma Amyloid-beta 42/40 Assays in Alzheimer Disease

Shorena Janelidze et al.

Summary: The study conducted in three different hospitals in Sweden from 2010 to 2014 found that certain mass spectrometry-based methods performed better for detecting brain A beta pathology compared to most immunoassays for plasma A beta 42/40 in patients with early Alzheimer's disease.

JAMA NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Prediction of Alzheimer's disease diagnosis within 14 years through Aβ misfolding in blood plasma compared to APOE4 status, and other risk factors

Hannah Stocker et al.

ALZHEIMERS & DEMENTIA (2020)

Add to Collection

Article Clinical Neurology

Plasma tau, neurofilament light chain and amyloid-beta levels and risk of dementia; a population-based cohort study

Frank de Wolfa et al.

BRAIN (2020)

Add to Collection

Article Clinical Neurology

Comparing progression biomarkers in clinical trials of early Alzheimer's disease

Nicholas C. Cullen et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)

Add to Collection

Article Immunology

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease

Nicolas R. Barthelemy et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

Add to Collection

Article Clinical Neurology

Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study

Kumar B. Rajan et al.

ANNALS OF NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease

Christoforos Hadjichrysanthou et al.

ALZHEIMERS RESEARCH & THERAPY (2020)

Add to Collection

Article Clinical Neurology

Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

Inge M. W. Verberk et al.

ALZHEIMERS RESEARCH & THERAPY (2020)

Add to Collection

Article Clinical Neurology

Mass spectrometry measures of plasma Aβ, tau and P‐tau isoforms’ relationship to amyloid PET, tau PET, and clinical stage of Alzheimer’s disease

Randall J. Bateman et al.

Alzheimers & Dementia (2020)

Add to Collection

Article Clinical Neurology

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline

Julia Stockmann et al.

ALZHEIMERS RESEARCH & THERAPY (2020)

Add to Collection

Article Psychiatry

Incident depression and mortality among people with different types of dementia: results from a longitudinal cohort study

Laura Perna et al.

SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY (2019)

Add to Collection

Article Clinical Neurology

Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease

Philip S. J. Weston et al.

ALZHEIMERS RESEARCH & THERAPY (2019)

Add to Collection

Article Clinical Neurology

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

Suzanne E. Schindler et al.

NEUROLOGY (2019)

Add to Collection

Editorial Material Clinical Neurology

Neurofilament light chain - new potential for prediction and prognosis

Ian Fyfe

NATURE REVIEWS NEUROLOGY (2019)

Add to Collection

Article Neurosciences

Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment

Patrick Oeckl et al.

JOURNAL OF ALZHEIMERS DISEASE (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease

Oliver Preische et al.

NATURE MEDICINE (2019)

Add to Collection

Article Neurosciences

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration

Nicholas J. Ashton et al.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)

Add to Collection

Review Clinical Neurology

An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform

Danni Li et al.

NEUROLOGY AND THERAPY (2019)

Add to Collection

Article Clinical Neurology

Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease

Andreas Nabers et al.

ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING (2019)

Add to Collection

Review Clinical Neurology

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

Clifford R. Jack et al.

ALZHEIMERS & DEMENTIA (2018)

Add to Collection

Article Medicine, Research & Experimental

Amyloid blood biomarker detects Alzheimer's disease

Andreas Nabers et al.

EMBO MOLECULAR MEDICINE (2018)

Add to Collection

Article Biochemical Research Methods

An infrared sensor analysing label-free the secondary structure of the Abeta peptide in presence of complex fluids

Andreas Nabers et al.

JOURNAL OF BIOPHOTONICS (2016)

Add to Collection

Article Chemistry, Analytical

Amyloid-β-Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer's Disease

Andreas Nabers et al.

ANALYTICAL CHEMISTRY (2016)

Add to Collection

Article Chemistry, Physical

Interaction of the Heparin-Binding Consensus Sequence of β-Amyloid Peptides with Heparin and Heparin-Derived Oligosaccharides

Khanh Nguyen et al.

JOURNAL OF PHYSICAL CHEMISTRY B (2016)

Add to Collection

Article Geriatrics & Gerontology

Association between Oxidative Stress and Frailty in an Elderly German Population: Results from the ESTHER Cohort Study

Kai-Uwe Saum et al.

GERONTOLOGY (2015)

Add to Collection

Review Clinical Neurology

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

Bruno Dubois et al.

LANCET NEUROLOGY (2014)

Add to Collection

Review Biochemistry & Molecular Biology

The Toxicity of Amyloid β Oligomers

Li Na Zhao et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)

Add to Collection

Article Clinical Neurology

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Guy M. McKhann et al.

ALZHEIMERS & DEMENTIA (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.